Neumirna Therapeutics
Overview
Neumirna Therapeutics is an innovative biotechnology company based in Copenhagen, Denmark, founded in 2020. The company specializes in developing RNA-based therapies aimed at disease modification for neurological disorders, with a particular focus on drug-resistant epilepsy and other conditions like Parkinson's disease. As of its latest Series A funding round in January 2025, co-led by Angelini Ventures and Invivo Partners, Neumirna has raised €20 million to further its research and development efforts.
Recent Developments
- January 2025: Neumirna Therapeutics raised €20 million in a Series A financing round. This significant investment was co-led by Angelini Ventures and Invivo Partners, with contributions from Innovestor’s Life Science Fund and other existing backers. The funding aims to advance the clinical development of Neumirna’s lead asset, NMT.001, a potential game-changing antisense oligonucleotide therapy for drug-resistant epilepsy. The company plans to expand its R&D capabilities and scale its pioneering drug discovery platform (BioSpace).
- 2024: Neumirna received a €1.65 million grant from the Eureka Network under the EUROSTARS program in collaboration with multiple partners to develop RNA therapies targeting Parkinson's Disease. Additionally, the company was awarded a $650,000 grant by The Michael J. Fox Foundation for Parkinson’s Research to propel RNA therapies for Parkinson's (Neumirna.com).
- October 2024: Researchers Victor Ambros and Gary Ruvkun were awarded the Nobel Prize for their work on microRNAs, a discovery significant for Neumirna's approach to leveraging microRNA-targeted therapies for neurological conditions.
- January 2024: Neumirna secured a third Innobooster grant of 5 million DKK to advance its epilepsy disease-modifying therapy towards clinical validation, demonstrating its ability to attract substantial financial support for its initiatives.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2020 |
| Headquarters | Copenhagen, Denmark |
| Founders | Dr. Henrik Klitgaard, Prof. Sakari Kauppinen, Lars Hellerung Christiansen |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Angelini Ventures, Invivo Partners, Innovestor’s Life Science Fund |
| Industry | Biotechnology |
| Number of Employees | 2-10 Employees |
Early History
Neumirna Therapeutics was established in 2020 by a team of experienced researchers and scientists, including Dr. Henrik Klitgaard, Prof. Sakari Kauppinen, and Lars Hellerung Christiansen. The company began with a mission to harness the potential of RNA technology to develop revolutionary therapeutics for complex neurological disorders. Neumirna initially secured seed funding from notable investors such as Sunstone Life Science Ventures and Innovestor, which facilitated foundational research and development. This early support laid the groundwork for the establishment of a robust drug discovery platform targeting microRNAs, paving the way for disease-modifying treatments.
Company Profile and Achievements
Neumirna Therapeutics operates with a clear focus on creating RNA therapies that offer disease-modifying potential, particularly for neurological disorders that are resistant to existing treatments. The company’s business model rests on its proprietary platform capable of exploiting microRNAs to address unmet medical needs by potentially halting or reversing disease progression. Key achievements include:
- Launching the development of NMT.001, a lead drug candidate designed to target drug-resistant epilepsy. Preclinical trials have shown promising efficacy, laying the groundwork for upcoming clinical validations.
- Establishing partnerships with academic institutions such as FutureNeuro for preclinical development, underscoring the collaborative approach to advancing clinical pipelines.
- Successfully securing Series A funding to expedite its R&D and enhance its technological platform, ensuring readiness for clinical trial phases (Silicon Republic).
- Garnering significant recognition through multiple grants, awards, and validations from scientific communities, bolstering its credibility and potential impact on the medical field.
Current Operations and Market Position
Neumirna Therapeutics is presently focused on translating its pioneering research into actionable clinical solutions. The company’s strategic positioning in the market revolves around its expertise in RNA therapies, targeting diseases with high therapeutic resistance such as drug-resistant epilepsy and Parkinson's disease. Neumirna's collaborations and alliances, notably with Angelini Ventures and other investors, have strengthened its market foothold, enhancing its ability to attract further investment and strategic partners. The biotech startup continues to elevate its competitive advantage by leveraging novel RNA technology that has shown unprecedented efficacy in preclinical studies.
Conclusion
Neumirna Therapeutics stands out in the biotech industry landscape for its commitment to transforming neurological disease treatment through innovative RNA-based therapies. With a strategic focus on disease-modifying approaches and robust financial backing highlighted by its successful Series A funding, the company is well-positioned to advance its lead candidate through clinical trials. Its pioneering work, supported by significant scientific milestones and collaborative partnerships, underpins its potential to effect substantial changes in patient care for traditionally intractable neurological disorders.